| Literature DB >> 18759739 |
Caroline BuBmann1, Thomas Bieber, Natalija Novak.
Abstract
Systemic therapy of severe atopic dermatitis (AD) is difficult in some cases, because the use of immunosuppressive agents such as cyclosporine A, mofetil mycophenolate, tacrolimus, and azathioprine is limited by adverse reactions or contraindications. Recent reports suggest a helpful role for biologics, methotrexate, anti-IgE antibodies, and immunotherapy. We review the modes of action, as well as advantages and disadvantages of current and new systemic therapeutic options for severe AD.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18759739 DOI: 10.1111/j.1610-0387.2008.06834.x
Source DB: PubMed Journal: J Dtsch Dermatol Ges ISSN: 1610-0379 Impact factor: 5.584